Chronische lymphatische Leukämie

• Literatur

• 1 Catovsky D, Richards S, Matutes E et al. UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial). Lancet 2007; 370: 230-239
• 2 Eichhorst BF, Busch R, Stilgenbauer S et al. German CLL Study Group (GCLLSG). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114: 3382-3391
• 3 Extermann M, Meyer J, McGinnis M et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 2004; 49: 69-75
• 4 Fischer K, Cramer P et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29: 3559-3566
• 5 Foa R, Ciolli S, Di Raimondo F et al. Rituximab plus chlorambucil as initial treatment for elderly patients with chronic lymphocytic leukemia (CLL): Effect of pre-treatment biological characteristics and gene expression patterns on response to treatment. Blood (ASH Annual Meeting Abstracts) 2011; 118: 294
• 6 Geisler CH, van't Veer MMB et al. Immunochemotherapy with low-dose subcutaneous alemtuzumab (A) plus oral fludarabine and cyclophosphamide (FC) is safe and induces more and deeper complete remissions in untreated patients with high-risk chronic lymphocytic leukemia (CLL) than chemotherapy with FC alone. An early analysis of the randomized phase-III HOVON68 CLL Trial. Blood (ASH Annual Meeting Abstracts) 2011; 118: 290
• 7 Hallek M, Fischer K, Fingerle-Rowson G et al. International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemial. Lancet 2010; 376: 1164-1174
• 8 Herman SE, Gordon AL, Hertlein E et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117: 6287-6296
• 9 Herman SE, Gordon AL, Wagner AJ et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078-2088
• 10 Hillmen P, Gribben JG, Follows GA et al. An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL). Blood (ASH Annual Meeting Abstracts) 2009; 114: 3428
• 11 James DF, Brown JR, Werner L et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia (CLL). A multicenter study of the CLL Research Consortium. Blood (ASH Annual Meeting Abstracts) 2011; 118: 291
• 12 Keating MJ, O'Brien S et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079-4088
• 13 O'Brien S, Burger JA, Blum KA et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II study. Blood (ASH Annual Meeting Abstracts) 2011; 118: 983
• 14 Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20: 1441-1445
• 15 Sharman J et al. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3K δ) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2011; 118: 1787
• 16 Stilgenbauer S, Cymbalista F et al. Alemtuzumab plus oral dexamethasone, followed by alemtuzumab maintenance or allogeneic transplantation in ultra high-risk CLL: Interim analysis of a phase II study of the GCLLSG and fcgcll/MW. Blood (ASH Annual Meeting Abstracts) 2011; 118: 2854
• 17 Wendtner CM, Dreger P, Gregor M, Greil R, Knauf W, Schetelig J, Steurer M, Stilgenbauer S. Chronische Lymphatische Leukämie (CLL). http://www.dgho-onkopedia.de/onkopedia/leitlinien/cll